Dive into the Biopharma Space

The bio/pharma IPO market reopened in H1 2026, as we predicted based on the bullish public bio/pharma market starting in the 2nd half of 2025. However, the bio/pharma IPO activity remains far below its historical peak in 2020/2021. BPIQ recorded 15 IPOs in H1 2026, up 114% from seven in H1 2025. This was the highest first-half total since 2021, but only narrowly above the 14 IPOs recorded in H1 2022 and still far below the 61 recorded in H1 2021. Quarterly Activity Shows a Gr

H1 2026 private bio/pharma funding reached its highest total amount invested in the past three years, but the number of funding events declined by almost 33%. Total capital increased slightly compared with H1 2024 and H1 2025, while funding activity remained well below prior-year levels. This points to an investment environment where capital is still available, but fewer companies are securing it. In total, private companies raised approximately $20.3B across 366 funding even

Q1 2026 private biotech funding remains low and did not match the January-driven peak seen in early 2025, but overall capital deployment remained broadly comparable. Unlike Q1 2025’s front-loaded start, funding in Q1 2026 was more evenly distributed across the quarter, pointing to a more stable, though still selective, investment environment. We still believe the stage is set for a rebound in private biotech funding starting in the 2nd half of 2026. In total, private companie

Private bio/pharma funding in 2025 totaled approximately $40.0 B across 1,045 private funding events, slightly below 2024’s $40.4 B , but substantially below 2024’s 1,367 deals (FN1). Activity was heavily front-loaded, with January 2025 alone accounting for $6.3 B and 138 deals , the single most active month of the year. After a mid-year lull in deal volume and capital deployment, the market saw modest late-year momentum, particularly in October ($6.0 B) and December ($3

After a difficult 3 years of private biotech funding for early-stage biotech companies (FN1, FN2), we predict that 2026 will be a breakout year. Why? 1. Public smid-cap biotech stocks soared in the 2nd half of 2025; 2. Historical data shows that when public smid-cap biotech stocks soar, the biotech IPO market opens up the following year; 3. Once the biotech IPO market opens, private funding should follow in subsequent quarters 1. Public smid-cap biotech stocks soared in the 2

Europe has rapidly become one of the world’s most dynamic regions for genetic analysis, sequencing technologies, and data-driven precision medicine. From liquid biopsies and transplant monitoring to next-generation bioinformatics platforms, a wave of innovative companies is redefining how genetic data is generated, interpreted, and applied in real clinical settings. At BiopharmIQ , we track 141 active European companies operating in genetic analysis, sequencing, and enablin

Seattle continues to make waves in the life sciences arena, blending the city’s deep research heritage with a new generation of biotech innovation. From next-generation antibody-drug conjugates to advanced RNA vaccines, the Emerald City is home to companies pushing the boundaries of how we diagnose, treat, and understand disease. Here are 10 companies to watch in 2025 , each driving fresh breakthroughs through clinical success, funding momentum, or technological innovation.

Southern California has long been known for its beaches and biotech, and nowhere is the region’s innovation more evident than in its antibody ecosystem . From San Diego’s wet labs to Pasadena’s protein engineers , the area has become a proving ground for companies blending creativity, capital, and clinical progress. At BiopharmIQ, we’ve tracked more than a hundred SoCal bio/pharma's developing antibody-based drugs, and we’ve handpicked 10 companies to watch in 2025 , chosen

" Private bio/pharma funding activity strengthened in September, reaching its highest level since early 2025 and reflecting a gradual re-acceleration in deal flow. " September 2025 marks the end of the third quarter with a significant uptick in deal activity , even though total dollars raised remain below early-year highs. The market continues to favor non-dilutive funding and smaller financings, with grants leading by deal count and early-stage rounds bouncing back from th

At BiopharmIQ , we’ve mapped over 280 biotech and pharma companies in Texas, tracking the rapid evolution of one of the most dynamic innovation hubs in the U.S. What once was a regional life sciences cluster is now a full-fledged ecosystem, where emerging bio/pharmas, mid-sized innovators, and major pharmaceutical players converge. This year’s landscape highlights clinical-stage activity, late preclinical acceleration, and significant capital infusions across therapeutic are

At BiopharmIQ , we’ve mapped 377 companies in the global AAV landscape . This work gave us a broad view of the ecosystem, from vector engineering innovators to clinical-stage pioneers and emerging players in new geographies. While big pharma has made major moves into AAV, this list focuses on bio/pharmas and mid-sized innovators that stand out for their technology novelty, recent funding, promising clinical results, or regulatory momentum . Do you have them on your radar? 👁

"Private bio/pharma funding rebounded in value in August, though deal counts remain subdued." August 2025 marked the seventh consecutive...

Radiopharmaceuticals are rapidly gaining attention across the biopharma industry, combining targeted delivery with therapeutic...

Cell therapy continues to be one of the most dynamic segments of biotech and pharma financing in 2025. From oncology to neurology,...

2025 Bio/Pharma Funding Trends: July’s Update

In Q1 2025, 26 new and emerging bio/pharma companies were identified, with the majority based in the U.S.—California and Massachusetts leading the count. Most of these companies focus on therapeutics, signaling strong investor interest. Verdiva Bio topped funding with $411M, followed by Kardigan and Windward Bio. Explore geographic trends, sector focus, and top-funded startups in our latest biopharmIQ report.

Gene editing has emerged as one of the most transformative technologies in biotech and pharma, with applications spanning therapeutics,...

The latest wave of new and emerging biologic companies in 2024 highlights a continued diversity of technology areas with a strong focus...

This annual report analyzes our biopharmIQ data on new/emerging bio/pharma companies for 2024 to provide insights into the geographic and...

We identified two (2) new or newly emerging biotech companies for December 2024. To find these new/emerging bio/pharma companies, every...